Blinatumomab clinical trials
Also written Blincyto, MT103 and AMG 103.
How each study uses blinatumomab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the blinatumomab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 3 Dec 2014 · BLINCYTO · BLA 125557 (FDA, Drugs@FDA)
- European Union
- 23 Nov 2015 · Blincyto · EMEA/H/C/003731 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
127 studies that test it; most in 2024 (15); 1 more planned to start later
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 5 |
| 2017 | 14 |
| 2018 | 11 |
| 2019 | 8 |
| 2020 | 7 |
| 2021 | 11 |
| 2022 | 6 |
| 2023 | 8 |
| 2024 | 15 |
| 2025 | 12 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 29 · Other 99
Amgen (18) · M.D. Anderson Cancer Center (13) · National Cancer Institute (NCI) (9) · Institute of Hematology & Blood Diseases Hospital, China (9) · Amgen Research (Munich) GmbH (7) · St. Jude Children's Research Hospital (4) · Goethe University (4) · The First Affiliated Hospital of Soochow University (4)
Often tested with
Tested in the same studies.
Venetoclax (10) · Inotuzumab Ozogamicin (10) · Prednisone (6) · Cyclophosphamide (5) · Cytarabine (5) · Ponatinib (5) · Thioguanine (4) · Dexamethasone (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Blinatumomab is the comparator. A study of two new drugs counts under both.
- 1Anti-CD19/CD3 Bispecific Antibody MK-1045 · Merck Sharp & Dohme LLC · next primary completion Oct 2033
- 1Ruxolitinib · Bambino Gesù Hospital and Research Institute · next primary completion Nov 2032
- 1Cyclophosphamide · Bambino Gesù Hospital and Research Institute · next primary completion Nov 2032
Reaching primary completion within a year · 18, 4 in phase 3
Studies that test blinatumomab, phase 3 first.
- Sep 2027Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLPhase 3 · Gruppo Italiano Malattie EMatologiche dell'Adulto
- Sep 2027Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute LeukemiaPhase 3 · Princess Maxima Center for Pediatric Oncology
- Sep 2027A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPhase 3 · National Cancer Institute (NCI)
- Oct 2027A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALLPhase 3 · Institute of Hematology & Blood Diseases Hospital, China
- Nov 2026Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaPhase 2 · M.D. Anderson Cancer Center
- Dec 2026Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission MaintenancePhase 1/2 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Dec 2026Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After TransplantationPhase 4 · Suping ZHANG
- Feb 2027Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaPhase 2 · National Cancer Institute (NCI)
- Feb 2027Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic LeukemiaPhase 2 · Northside Hospital, Inc.
Studies
Open first, then newest update. How each study uses blinatumomab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 128
- A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1M.D. Anderson Cancer CenterNCT07283640Written as Blinatumomab
- Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT03739814Written as Blinatumomab
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT04546399Written as Blinatumomab
- Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)RecruitingPhase 1/2Novartis PharmaceuticalsNCT07387926Written as Blinatumomab
- Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03263572Written as Blinatumomab
- Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06308588Written as Blinatumomab
- A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT07313852Written as Blinatumomab Injection
- Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLNot yet recruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07921550Written as Blinatumomab
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as Blinatumomab
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)RecruitingPhase 3Charite University, Berlin, GermanyNCT07476729Written as Blinatumomab
- Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute LeukemiaRecruitingPhase 3Princess Maxima Center for Pediatric OncologyNCT05327894Written as Blinatumomab
- Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaRecruitingPhase 1City of Hope Medical CenterNCT07133997Written as Blinatumomab
- Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic LeukemiaRecruitingPhase 2Northside Hospital, Inc.NCT05519579Written as Blinatumomab
- A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesRecruitingPhase 2AmgenNCT06570798Written as Blinatumomab
- Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's SyndromeNot yet recruitingPhase 2Beijing Tongren HospitalNCT07852234Written as Blinatumomab
- Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT05645718Written as Blinatumomab
- A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic LeukaemiaNot yet recruitingPhase 3AmgenNCT07223190Written as Blinatumomab
- Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNot applicableFirst Affiliated Hospital of Zhejiang UniversityNCT07003737Written as Blinatumomab
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingPhase 3Children's Oncology GroupNCT03959085Written as Blinatumomab
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaRecruitingPhase 3Mats HeymanNCT04307576Written as Blinatumomab
See all 128 studies that test blinatumomab →
Given beside what is tested · 21 — blinatumomab is usual care or a partner of the new treatment
- TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIRecruitingPhase 1/2Tanja Andrea GruberNCT05848687Written as Blinatumomab
- Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1City of Hope Medical CenterNCT07914166Written as Blinatumomab
- Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07604233Written as Blinatumomab
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as Blinatumomab
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingPhase 2SWOG Cancer Research NetworkNCT07636564Written as Blinatumomab
- Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)Not yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07178912Written as Blinatumomab
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07840976Written as Blinatumomab
- ALL Backbone in AYAsRecruitingPhase 2Dana-Farber Cancer InstituteNCT07227584Written as Blinatumomab
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic LeukemiaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07495631Written as Blinatumomab
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07493161Written as Blinatumomab
- Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and LymphomaRecruitingPhase 2St. Jude Children's Research HospitalNCT06533748Written as Blinatumomab
- Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT01371630Written as Blinatumomab
- ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07454226Written as Blinatumomab
- A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute LeukemiaNot yet recruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07573670Written as Blinatumomab
- CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLRecruitingPhase 1/2University of ChicagoNCT07294677Written as Blinatumomab
- Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLRecruitingPhase 1Ascentage Pharma Group Inc.NCT04260022Written as Blinatumomab
- ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLRecruitingPhase 1Marlise Luskin, MDNCT03595917Written as Blinatumomab
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02143414Written as Blinatumomab
- Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxActive, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT05192889Written as Blinatumomab
- Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow LymphoblastsCompletedPhase 1/2University of California, San DiegoNCT03160079Written as blinatumomab
Showing 20 of 21.
As the comparator · 3 — what is tested is compared with blinatumomab
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07570173Written as Blinatumomab
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLRecruitingPhase 2/3Bambino Gesù Hospital and Research InstituteNCT07297914Written as Blinatumomab
- Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic LeukemiaWithdrawnPhase 3Novartis PharmaceuticalsNCT03628053Written as Blinatumomab
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Results posted1
Newly registered1
Codes
What other systems call blinatumomab · ClinicalTrials.gg INT004918
- MeSH (NLM) C510808blinatumomabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4FR53SIF3ABLINATUMOMABConfirmed FDA, NLM, Wikidata
- RxNorm 1597258Confirmed FDA, Wikidata
- Wikidata Q410189blinatumomabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62528BlinatumomabOne source FDA
- DrugBank DB09052One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C510808 | blinatumomab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4FR53SIF3A | BLINATUMOMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1597258 | — | Confirmed FDA, Wikidata |
| Wikidata | Q410189 | blinatumomab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62528 | Blinatumomab | One source FDA |
| DrugBank | DB09052 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.